Hidradenitis Suppurativa Clinical Trials Recruiting Now: NAV-240 Phase 2 Study in Phoenix, Miami, Tampa and More

Hidradenitis Suppurativa (HS) is a chronic, painful inflammatory skin condition that causes painful lumps, abscesses, and draining tunnels under the skin, most commonly in areas like the armpits, groin, buttocks, and under the breasts. For the estimated 1-4% of people affected worldwide, HS can severely impact quality of life, mobility, and mental health. While current treatments include antibiotics, biologics like adalimumab, and surgery for advanced cases, many patients do not achieve adequate control.

Clinical trials are testing new options. One actively recruiting Phase 2 study is evaluating NAV-240, a novel therapy, for moderate-to-severe HS.

Actively Recruiting Trial: NAV-240 (NCT07384975)

NCT ID: NCT07384975
Sponsor: Navigator Medicines, Inc.
Phase: 2
Status: RECRUITING
Key Locations (United States):

• Phoenix, Arizona (Medical Dermatology Specialist)
• Maitland, Florida (Accel Research Sites Network)
• Miami, Florida (multiple sites including Floridian Research Institute, Cordova Research Institute)
• North Miami Beach, Florida (Tory Sullivan MD PA - Dermatology)
• Tamarac, Florida (MplusM - D&H Tamarac Research Center)
• Tampa, Florida (ForCare Clinical Research)
• Murray, Kentucky (Kentucky Advanced Medical Research LLC)
• Portsmouth, New Hampshire (ActivMed Practices & Research, LLC)
• The Bronx, New York (Equity Medical, LLC)

Study Design Highlights:

• Randomized, double-blind, placebo-controlled.
• Participants receive NAV-240 (dose 1 or dose 2) or placebo via intravenous (IV) infusion.
• Primary endpoint: Percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16 — at least a 75% reduction in abscess and inflammatory nodule (AN) count, with no increase in draining tunnels.
• Duration: Up to 22 weeks (9 clinic visits).
• Participants keep a daily diary about skin pain.

Key Eligibility Criteria (summary):

• Adults 18–70 years old.
• History of HS for at least 6 months.
• At least 5 abscesses and inflammatory nodules.
• Inflammatory lesions in at least 2 different body regions, with at least one Hurley Stage II or III.
• Inadequate response to at least one course of antibiotics.
• Stable oral antibiotics (doxycycline, minocycline, or tetracycline) allowed if dose unchanged until Week 16.
• Negative pregnancy test for women of childbearing potential; use of highly effective contraception required.

Exclusions include: More than 20 draining tunnels, active infections requiring certain antibiotics, recent major surgery, certain infections (HIV, hepatitis, TB), recent heart issues, or immune deficiency.

This trial aims to determine if NAV-240 is more effective than placebo for reducing HS lesions in patients with moderate-to-severe disease who have not responded well to standard antibiotics.

Standard Treatments vs. Investigational Approaches in HS Trials

Approach	Examples	Typical Use Case	Limitations
Antibiotics (oral/topical)	Doxycycline, clindamycin	Mild-moderate HS, infection control	Resistance, limited long-term efficacy
Biologics	Adalimumab (Humira)	Moderate-severe HS	Not effective for all; injection site reactions
Surgery	Incision & drainage, excision	Severe, localized disease	Recurrence common; scarring
Investigational (e.g. NAV-240)	IV therapy targeting new pathways	Moderate-severe, antibiotic-refractory	Early phase; long-term safety data pending

Note: This is for informational purposes only. Eligibility and outcomes are determined by the study team.

How Corterve Helps Patients Find HS Trials

Corterve's platform matches patients to recruiting clinical trials using:

• Condition-specific search (e.g., "hidradenitis suppurativa" or "HS").
• Location and travel radius filtering.
• Structured pre-screening based on age, disease history, lesion count, and prior treatments.
• Direct referral to study sites when you pre-qualify.

Search actively recruiting Hidradenitis Suppurativa trials: Corterve HS Trials

Get personalized alerts: Register with your ZIP code to be notified of new studies near you.

Questions to Ask Your Dermatologist or Study Team

• Is my HS considered moderate-to-severe based on Hurley staging and lesion count?
• Have I tried the required prior antibiotics or biologics?
• What are the potential side effects of NAV-240 or similar investigational drugs?
• How many visits are required, and is travel support available?
• What happens after the 16-week primary endpoint period?
• Are there other open HS trials (e.g., new biologics, oral agents, or combination therapies) that might fit my situation better?

Important: Pre-qualification on Corterve is a first step only. The research site's team makes the final eligibility determination after full medical review, including exams and labs. HS is a complex condition—always discuss treatment options, including clinical trials, with your board-certified dermatologist or HS specialist.

Disclaimer: Corterve is a clinical trial matching platform, not a medical provider. We do not give medical advice, diagnose conditions, or guarantee trial eligibility or outcomes. All eligibility determinations and medical decisions are made by the study's research team and your healthcare providers. This post uses publicly available trial metadata for informational purposes only. Consult a qualified healthcare professional before considering any clinical trial or changing your treatment plan.